Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

Solventum (SOLV)

NYSE: SOLV · Health Care Technology · Eagan, MN

Our rating: Cautious

Cautious reaffirmed at $90.38, moderate conviction, November 6, 2026.

Breaks if: The cautious call is wrong if free cash flow recovers to above $400 million over any two consecutive reported quarters within the next twelve months — a level that would confirm the earnings-to-cash gap is closing rather than entrenched — or if year-over-year revenue growth reaches 4% or higher in any quarterly filing within the same period. Either development would require revisiting whether the low multiple is a genuine entry point rather than a reflection of structural problems.

Key figures

Market value$14.3B
Revenue, last 12 months$8.2B
Net income, last 12 months$156M
Free cash flow, last 12 months$0.00
Price to earnings91.9×
Free cash flow yield0.0%
Dividend yield0.0%
Operating margin5.6%
Return on equity3.2%
Beta to the S&P 5000.75
Volatility, annualized30.7%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026$1.9B−7.0%$-0.07$97M
June 30, 2026$2.2B2.2%$0.53$144M
March 31, 2026$2.0B−3.0%$0.07−$273M
December 31, 2025$2.0B−3.7%$0.35$32M
September 30, 2025$2.1B0.7%$7.22−$21M
June 30, 2025$2.2B3.8%$0.51$59M
March 31, 2025$2.1B2.7%$0.78−$80M
December 31, 2024$2.1B1.9%$0.18$92M

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

9 ledger entries and 12 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.